Last reviewed · How we verify

Kaizen Bioscience Co. — Portfolio Competitive Intelligence Brief

Kaizen Bioscience Co. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Amoxicillin potassium clavulanate Amoxicillin potassium clavulanate marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); bacterial beta-lactamases Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Asian Institute of Gastroenterology, India · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva · 1 shared drug class
  5. Hospital Italiano de Buenos Aires · 1 shared drug class
  6. Imperial College London · 1 shared drug class
  7. Maggiore Bellaria Hospital, Bologna · 1 shared drug class
  8. Albany Medical College · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kaizen Bioscience Co.:

Cite this brief

Drug Landscape (2026). Kaizen Bioscience Co. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kaizen-bioscience-co. Accessed 2026-05-15.

Related